RxDoctor Payments Data

Elizabeth Patterson, APRN

Family · North Platte, NENPI 1275200131

Payments from drug & device makers

$1,652in general payments, 2019–2025

Across 92 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$506
  • Abbott$147
  • E.r. Squibb & Sons, L.L.C.$146
  • AstraZeneca$136
  • Johnson & Johnson$131
  • Boston Scientific$107
  • plus $481 from 13 others

What the payments were for

  • Food & beverage$1,59897%
  • Education$543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,652 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$2,149
Medicare patients
83
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten19$159,610
EliquisApixaban91$53,866
JardianceEmpagliflozin64$36,524
XareltoRivaroxaban41$36,074
EntrestoSacubitril/Valsartan30$20,655
Repatha SureclickEvolocumab19$14,139
BrilintaTicagrelor26$12,807
FarxigaDapagliflozin Propanediol18$9,911
Atorvastatin Calcium175$2,496
Ezetimibe96$2,123
Enoxaparin Sodium14$1,706
ClopidogrelClopidogrel Bisulfate107$1,420
Metoprolol Succinate79$962
Potassium Chloride33$957
Rosuvastatin Calcium82$945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$146$159,61019 claims
PfizerEliquis$15$53,86691 claims
Boehringer IngelheimJardiance$25$36,52464 claims
Johnson & JohnsonXarelto$131$36,07441 claims
AstraZenecaBrilinta, Farxiga$136$22,71844 claims
NovartisEntresto$506$20,65530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.

Other family in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →